Publications by authors named "Fred Lublin"

Claim this Profile
I
Identification of risk profiles for liver injury in adults with multiple sclerosis using artificial intelligence method.
Dominique Larrey, Fang Liz Zhou, Claire Brulle-Wohlhueter, Myriam Benamor, Jeffrey Chavin, Fred Lublin

Mult Scler Relat Disord· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Black and Non-Hispanic White persons with multiple sclerosis: Social determinants of health and health inequities.
Marta Ponzano, Nicole Graziano, Claire Wigley, Giacomo Boffa, Sylvia Klineova, Fred Lublin

Mult Scler Relat Disord· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Depression Polygenicity and Disease Activity and Disability Worsening in Multiple Sclerosis.
Ali Manouchehrinia, Kathryn C Fitzgerald, Amber Salter, Ruth Ann Marrie, Lars Alfredsson, Fred D Lublin

Ann Neurol· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cognition in multiple sclerosis within the modern diagnostic and treatment era.
James F Sumowski, Sarah Levy, Ilana Katz Sand, Rachel Brandstadter, Emily Dvorak, Fred D Lublin

Brain· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Ponesimod as add-on treatment in patients with active relapsing multiple sclerosis under dimethyl fumarate (POINT): A phase 3, randomized, placebo-controlled clinical trial.
Ludwig Kappos, Michel Burcklen, Daniele D'Ambrosio, Robert J Fox, Mark S Freedman, Fred Lublin

Mult Scler Relat Disord· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
AI-driven reclassification of multiple sclerosis progression.
Habib Ganjgahi, Dieter A Häring, Piet Aarden, Gordon Graham, Yang Sun, Fred D Lublin

Nat Med· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Diagnosis of multiple sclerosis: 2024 revisions of the McDonald criteria.
Xavier Montalban, Christine Lebrun-Frénay, Jiwon Oh, Georgina Arrambide, Marcello Moccia, Fred Lublin

Lancet Neurol· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Composite Confirmed Disability Worsening/Progression Is a Useful Clinical Endpoint for Multiple Sclerosis Clinical Trials.
Ludwig Kappos, Sean Yiu, Frank Dahlke, Timothy Coetzee, Gary R Cutter, Fred D Lublin

Neurology· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Relationship between sodium and diffusion MRI metrics in multiple sclerosis.
Emilio Cipriano, Giacomo Boffa, Nicole Graziano, Claire Wigley, Maria Petracca, Fred Lublin

Brain Commun· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treating to target in multiple sclerosis: Do we know how to measure whether we hit it?
Gabriel Bsteh, Nik Krajnc, Patrick Altmann, Barry Hendin, Trishna Bharadia, Fred Lublin

Eur J Neurol· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Polygenic liability for anxiety in association with comorbid anxiety in multiple sclerosis.
Kaarina Kowalec, Arvid Harder, Casandra Dolovich, Kathryn C Fitzgerald, Amber Salter, Fred D Lublin

Ann Clin Transl Neurol· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Relapse recovery in relapsing-remitting multiple sclerosis: An analysis of the CombiRx dataset.
Marcus W Koch, Ester Moral, Luis Brieva, Jop Mostert, Eva Mm Strijbis, Fred D Lublin

Mult Scler· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
W
Worsening MS-A reappraisal of how we characterize the MS disease course.
Fred D Lublin

Mult Scler· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Do the current MS clinical course descriptors need to change and if so how? A survey of the MS community.
Alan J Thompson, Marcello Moccia, Maria Pia Amato, Peter A Calabresi, Marcia Finlayson, Fred D Lublin

Mult Scler· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Polygenicity of Comorbid Depression in Multiple Sclerosis.
Kaarina Kowalec, Kathryn C Fitzgerald, Amber Salter, Casandra Dolovich, Arvid Harder, Fred Lublin

Neurology· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy of nabiximols oromucosal spray on spasticity in people with multiple sclerosis: Treatment effects on Spasticity Numeric Rating Scale, muscle spasm count, and spastic muscle tone in two randomized clinical trials.
Jacqueline Nicholas, Fred Lublin, Sylvia Klineova, Joris Berwaerts, Robert Chinnapongse

Mult Scler Relat Disord· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of baseline age and disease duration on the efficacy and safety of siponimod in patients with active SPMS: Post hoc analyses from the EXPAND study.
Le H Hua, Amit Bar-Or, Stanley L Cohan, Fred D Lublin, Patricia K Coyle

Mult Scler Relat Disord· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
MS becomes a treatable disease: 30 years later.
Fred D Lublin, Stephen C Krieger

Mult Scler· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The impact of relapse definition and measures of durability on MS clinical trial outcomes.
Sammita Satyanarayan, Gary Cutter, Stephen Krieger, Stacey Cofield, Jerry S Wolinsky, Fred Lublin

Mult Scler· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Serum neurofilament light-chain levels and long-term treatment outcomes in relapsing-remitting multiple sclerosis patients: A post hoc analysis of the randomized CombiRx trial.
Gary Cutter, Richard A Rudick, Carl de Moor, Carol M Singh, Elizabeth Fisher, Fred D Lublin

Mult Scler J Exp Transl Clin· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation of immunological responses to third COVID-19 vaccine among people treated with sphingosine receptor-1 modulators and anti-CD20 therapy.
Ilana Katz Sand, Sacha Gnjatic, Florian Krammer, Kevin Tuballes, Juan Manuel Carreño, Fred Lublin

Mult Scler Relat Disord· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation of neurotrophic factor secreting mesenchymal stem cells in progressive multiple sclerosis.
Jeffrey A Cohen, Fred D Lublin, Christoper Lock, Daniel Pelletier, Tanuja Chitnis

Mult Scler· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Disability outcomes in early-stage African American and White people with multiple sclerosis.
Maria Petracca, Raffaele Palladino, Amgad Droby, Daniel Kurz, Nicole Graziano, Fred Lublin

Mult Scler Relat Disord· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Association of Vitamin D Polygenic Risk Scores and Disease Outcome in People With Multiple Sclerosis.
Eleni S Vasileiou, Chen Hu, Charles N Bernstein, Fred Lublin, Jerry S Wolinsky

Neurol Neuroimmunol Neuroinflamm· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Predictors of Disease Activity and Worsening in Relapsing-Remitting Multiple Sclerosis.
Yinan Zhang, Stacey Cofield, Gary Cutter, Stephen Krieger, Jerry S Wolinsky, Fred Lublin

Neurol Clin Pract· August 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis